Poor attainment of lipid targets in patients with symptomatic peripheral artery disease

JF Dopheide, L Papac, M Schindewolf… - Journal of clinical …, 2018 - Elsevier
Background Patients with peripheral artery disease (PAD) are at very high risk of future
cardiovascular (CV) events. Strict lipid-lowering therapy is recommended. However, data on …
被引用次数：23 相关文章

Poor attainment of lipid targets in patients with symptomatic peripheral artery disease.

JF Dopheide, L Papac, M Schindewolf… - Journal of clinical …, 2018 - boris.unibe.ch
BACKGROUND Patients with peripheral artery disease (PAD) are at very high risk of future
cardiovascular (CV) events. Strict lipid-lowering therapy is recommended. However, data on …

Poor attainment of lipid targets in patients with symptomatic peripheral artery disease.

JF Dopheide, L Papac, M Schindewolf… - Journal of clinical …, 2018 - sonar.ch
OBJECTIVE The objective of the study was to investigate guideline equitable lipid lowering
in a large observational study of symptomatic PAD patients. METHODS Single-center …

Poor attainment of lipid targets in patients with symptomatic peripheral artery disease

JF Dopheide, L Papac… - Journal of clinical …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Patients with peripheral artery disease (PAD) are at very high risk of future
cardiovascular (CV) events. Strict lipid-lowering therapy is recommended. However, data on …

Poor attainment of lipid targets in patients with symptomatic peripheral artery disease

JF Dopheide, L Papac, M Schindewolf… - Journal of Clinical …, 2018 - lipidjournal.com
Background Patients with peripheral artery disease (PAD) are at very high risk of future
cardiovascular (CV) events. Strict lipid-lowering therapy is recommended. However, data on …

Poor attainment of lipid targets in patients with symptomatic peripheral artery disease.

JF Dopheide, L Papac, M Schindewolf… - Journal of Clinical …, 2018 - europepmc.org
Background Patients with peripheral artery disease (PAD) are at very high risk of future
cardiovascular (CV) events. Strict lipid-lowering therapy is recommended. However, data on …